Blueprint Medicines Co. (NASDAQ:BPMC) Director Sells $1,660,584.33 in Stock

Blueprint Medicines Co. (NASDAQ:BPMC - Get Free Report) Director Jeffrey W. Albers sold 15,161 shares of the stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $109.53, for a total transaction of $1,660,584.33. Following the completion of the transaction, the director now owns 152,396 shares of the company's stock, valued at $16,691,933.88. This trade represents a 9.05 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Blueprint Medicines Stock Up 4.1 %

NASDAQ:BPMC traded up $4.55 on Thursday, hitting $115.63. 1,479,676 shares of the company's stock traded hands, compared to its average volume of 990,877. The company has a market cap of $7.35 billion, a PE ratio of -54.80 and a beta of 0.61. Blueprint Medicines Co. has a 1 year low of $72.24 and a 1 year high of $121.90. The company has a current ratio of 3.32, a quick ratio of 3.27 and a debt-to-equity ratio of 1.09. The firm has a 50-day moving average price of $95.28 and a 200-day moving average price of $95.48.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last announced its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported ($0.89) EPS for the quarter, beating analysts' consensus estimates of ($0.97) by $0.08. Blueprint Medicines had a negative net margin of 29.48% and a negative return on equity of 112.30%. The firm had revenue of $128.20 million for the quarter, compared to the consensus estimate of $127.56 million. During the same period in the previous year, the firm posted ($2.20) earnings per share. The firm's revenue was up 126.5% on a year-over-year basis. Equities analysts anticipate that Blueprint Medicines Co. will post -3.67 EPS for the current fiscal year.

Wall Street Analyst Weigh In

BPMC has been the subject of a number of research reports. JPMorgan Chase & Co. started coverage on Blueprint Medicines in a research note on Thursday, November 14th. They set an "overweight" rating and a $126.00 price target for the company. Needham & Company LLC reaffirmed a "buy" rating and set a $135.00 target price on shares of Blueprint Medicines in a research note on Monday, January 13th. Stephens reiterated an "overweight" rating and issued a $140.00 price target on shares of Blueprint Medicines in a research report on Thursday, January 2nd. Wedbush restated an "outperform" rating and set a $124.00 price objective (down previously from $135.00) on shares of Blueprint Medicines in a research report on Monday, January 13th. Finally, Guggenheim reiterated a "buy" rating on shares of Blueprint Medicines in a report on Wednesday, December 11th. One analyst has rated the stock with a sell rating, seven have issued a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $122.72.

Hedge Funds Weigh In On Blueprint Medicines

Hedge funds have recently modified their holdings of the stock. Wellington Management Group LLP boosted its position in Blueprint Medicines by 22.5% during the third quarter. Wellington Management Group LLP now owns 3,964,610 shares of the biotechnology company's stock valued at $366,726,000 after purchasing an additional 729,055 shares during the last quarter. Millennium Management LLC raised its stake in shares of Blueprint Medicines by 540.0% during the 2nd quarter. Millennium Management LLC now owns 627,626 shares of the biotechnology company's stock worth $67,646,000 after purchasing an additional 529,566 shares in the last quarter. State Street Corp lifted its holdings in shares of Blueprint Medicines by 16.2% during the 3rd quarter. State Street Corp now owns 2,765,702 shares of the biotechnology company's stock valued at $255,827,000 after buying an additional 385,818 shares during the last quarter. Jacobs Levy Equity Management Inc. grew its stake in shares of Blueprint Medicines by 161.1% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 496,087 shares of the biotechnology company's stock valued at $45,888,000 after buying an additional 306,079 shares in the last quarter. Finally, Point72 Asset Management L.P. increased its holdings in Blueprint Medicines by 79.3% in the second quarter. Point72 Asset Management L.P. now owns 501,581 shares of the biotechnology company's stock worth $54,060,000 after buying an additional 221,813 shares during the last quarter.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.